BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial Contrast

Biopharma Stock With Layers of Technical Support in Place

BioCryst Eyes $1B Rare-Disease Future Through External Innovation

4 Biotech Stocks to Watch as Potential Takeover Targets

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

BioCryst to Present at Upcoming Investor Conference

Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX

Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve

Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet

BioCryst is profitable. Now it wants to buy more rare disease drugs

ADAR1 Capital Management LLC Takes $1.33 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Brokerages

Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?